Ubs Oconnor LLC Uni Qure N.V. Call Options Transaction History

Ubs Oconnor LLC

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $351,200 - $434,400	80,000 New	80,000 $358,000
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $3,378 - $4,962	600 Added 0.67%	90,600 $613,000
Q3 2023 Nov 14, 2023	BUY	$6.71 - $11.83 $342,210 - $603,330	51,000 Added 130.77%	90,000 $603,000
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $433,679 - $865,800	39,000 New	39,000 $975,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.